Oncoclínicas Loses Its Entire Board — and Has 15 Days of Cash Left

The Oncoclínicas board dissolution is the climax of a corporate crisis that has been building for over a year. Paradoxically, the collapse of governance may be the event that finally forces a resolution — because the company is now too broken to survive without one.

Oncoclínicas (B3: ONCO3) lost its entire board of directors on Monday after chair Marcelo Gasparino da Silva submitted his resignation. Under Brazil’s voto múltiplo system — which elects all board members as a single proportional slate — the departure of one member triggers the automatic dissolution of the rest. The company confirmed the Oncoclínicas board will be reconstituted at an extraordinary general meeting on April 30, leaving a 23-day governance vacuum at a company with 145 treatment centers, over 2,700 oncologists, and a cash position measured in days rather than months.

The Cash Emergency

The governance crisis arrives at the worst possible moment. Seu Dinheiro reported that Oncoclínicas has cash for approximately 15 more days of operations. The company has been unable to pay for cancer medications, forcing delays in treatment for roughly 3,000 patients in the past week alone, according to Valor Econômico. Severe and urgent cases are being transferred to partner hospitals. Doctors have begun leaving the network. The company has also requested waivers from debenture holders for a likely breach of its leverage covenant, signaling that its debt-to-EBITDA ratio has exceeded contractual limits.

The trajectory from IPO darling to near-insolvency has been steep. Oncoclínicas listed at R$19.75 per share in August 2021, raising R$3.6 billion ($666 million). The stock traded at R$1.54 on Tuesday — a 92% decline. Net debt reached R$3.3 billion ($640 million) by late 2025, and the company recorded a 97.9% decline in net income in Q3 2024. Two capital increases totaling R$3 billion failed to stabilize the balance sheet because the underlying problem was not underfunding but an aggressive acquisition spree that left the company overextended across too many facilities with insufficient operating margins.

Three Competing Rescues

The board dissolution clears the decks for a restructuring that the previous governance structure had been unable to deliver. Three competing proposals are now on the table. Mak Capital, which holds 6.3% of the company, has offered a R$500 million ($97 million) capital injection and nominated four independent board candidates for the April 30 election. The fund has been the most vocal activist, joining a crowded field of distressed-asset investors demanding governance reform and criticizing the current management’s track record.

Starboard, a distressed-asset specialist, proposed a more aggressive R$1 billion ($194 million) transaction that would convert creditor claims into equity, effectively wiping out or severely diluting existing shareholders. The Starboard proposal reportedly includes Fleury (B3: FLRY3), Brazil’s leading diagnostics group, as a co-investor — with a plan to carve the oncology clinics into a NewCo while leaving hospital operations and other assets with the parent. Separately, the Porto Seguro NewCo deal signed in March remains technically on the table, though the 30-day exclusivity window has expired amid the board turmoil.

Why the Stock Went Up

ONCO3 surged nearly 10% on Tuesday morning to R$1.54, one of the best-performing stocks on the B3 despite the headline catastrophe. The market read is straightforward: the board that presided over the crisis is gone, and the competing rescue bids — particularly Starboard’s debt-to-equity conversion with Fleury as a credible operating partner — represent a plausible path out of insolvency. The Mak Capital board nominations add an activist presence that investors believe will enforce the restructuring discipline that management failed to deliver on its own.

The risk is that none of the rescues close before the cash runs out. If no agreement is reached before the April 30 board election — or if the new board cannot immediately authorize emergency financing — Oncoclínicas could be forced into judicial recovery (the Brazilian equivalent of Chapter 11). That would trigger cross-default clauses across its R$3.3 billion debt stack and potentially disrupt care for the thousands of cancer patients who depend on the network. For a company that once represented Latin America’s ambition to build a world-class private oncology platform — and that partnered with Harvard’s Dana-Farber Cancer Institute — the countdown is now measured in days, not quarters.